LAM aims to apply methylation cancer testing to blood
The cancer blood testing company Laboratory for Advanced Medicine is ready to compete on price, which might be necessary in a market already thronged with products.
Deals and data in the offing for Oncimmune
Oncimmune is not the only company looking to use the immune system to diagnose cancer. But its growth plans are intense, and it intends to prove the economic benefits of…
Corporate VC activity in medtech increases – until this year
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
Boston and Coloplast sink on mesh mess
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.
Lukewarm data for Second Sight
Second Sight’s second product might lead the company to second place in the market.
Leviticus Cardio charges towards the market
A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
AACR 2019 – Guardant looks to its other liquid biopsy
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
ACC 2019 – Low risk of patients being denied transcatheter aortic valves
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.